Last reviewed 2026-04-20 · How we verify

Sunvepra (ASUNAPREVIR)

Sunvepra (ASUNAPREVIR) is a small molecule antiviral medication. It is used to treat chronic hepatitis C, a viral infection that causes liver damage. The commercial status of Sunvepra is patented, and it is currently owned by a pharmaceutical company. Key safety considerations include its potential to interact with other medications and its effect on liver function. Sunvepra is not off-patent.

At a glance

Approved indications

• Chronic hepatitis C

Common side effects

No common side effects on file.

Key clinical trials

• Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
• Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
• Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
• Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
• Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
• A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (PHASE3)
• Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (PHASE3)
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.